TCGA-ZF-AA4U-01A-11R-A38B-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 8.607095926
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.320
- MYC_TARGETS_V1+0.300
- MYC_TARGETS_V2+0.240
- PEROXISOME+0.240
- PROTEIN_SECRETION+0.230
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.200
- FATTY_ACID_METABOLISM+0.180
- GLYCOLYSIS+0.170
- CHOLESTEROL_HOMEOSTASIS+0.150
- TGF_BETA_SIGNALING+0.150
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.490
- ANGIOGENESIS-0.470
- INFLAMMATORY_RESPONSE-0.390
- HEDGEHOG_SIGNALING-0.370
- ALLOGRAFT_REJECTION-0.360
- MYOGENESIS-0.330
- G2M_CHECKPOINT-0.310
- E2F_TARGETS-0.280
- KRAS_SIGNALING_UP-0.280
- IL2_STAT5_SIGNALING-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ULC1533T_S61 | — | cohortA2 | 0.849 |
| 2 | SRR33346942 | — | — | 0.848 |
| 3 | TCGA-A8-A06Y-01A-21R-A00Z-07 | — | B | 0.844 |
| 4 | TCGA-4Z-AA89-01A-11R-A39I-07 | — | — | 0.841 |
| 5 | TCGA-E7-A5KF-01A-11R-A28M-07 | — | — | 0.837 |
| 6 | SRR6013506 | — | cohortA2 | 0.832 |
| 7 | ee24b470-4509-4687-a91e-6d2b967336b9 | — | — | 0.827 |
| 8 | X08d41e55.6d66.4e03.9dc3.3743f3da0453 | — | cohortA2 | 0.823 |
| 9 | 37b95452-c6ab-48f9-abd4-521b33596657 | — | — | 0.814 |
| 10 | TCGA-BH-A18S-01A-11R-A12D-07 | — | B | 0.814 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.240 | Idelalisib | — uncovered |
| PEROXISOME | 0.240 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.230 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.170 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.150 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.150 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.110 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.060 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.050 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.040 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.040 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.040 | Idelalisib | — uncovered |
| HYPOXIA | 0.020 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.020 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.020 | Inavolisib | — uncovered |